Jean Henry
Endocrinology, Diabetes & Metabolism · Branford, CTNPI 1023174745
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,015 of the $6,793 with a category attached, or 88.5%. It is spread thinly across 36 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,821 and has fallen 99.2% since, to $24 in 2023.
Across 361 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$834
- Valeritas, Inc.$800
- Lilly USA, LLC$505
- Sanofi-aventis U.S. LLC$494
- Amgen$463
- Abbott$424
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$75011%
- Travel & lodging$80%
- Food & beverage$6,01589%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 97 | $834 |
| Valeritas, Inc. | 4 | $800 |
| Lilly USA, LLC | 34 | $505 |
| Sanofi-aventis U.S. LLC | 30 | $494 |
| Amgen | 20 | $463 |
| Abbott | 21 | $424 |
| Amneal Pharmaceuticals LLC | 16 | $334 |
| AstraZeneca(2 entities) | 14 | $268 |
| Amarin Pharma, Inc. | 14 | $260 |
| AbbVie | 12 | $243 |
| Corcept Therapeutics | 6 | $226 |
| Mannkind Corporation | 9 | $211 |
| Merck | 13 | $205 |
| Insulet Corporation | 9 | $183 |
| Boehringer Ingelheim | 9 | $177 |
| Medtronic(2 entities) | 7 | $144 |
| IBSA Pharma Inc. | 8 | $143 |
| Bayer | 1 | $125 |
| Zealand Pharma US, Inc. | 4 | $91 |
| Radius Health, Inc. | 4 | $79 |
| Acerus Pharmaceuticals Corporation | 3 | $66 |
| BD | 3 | $64 |
| Aytu Biopharma, Inc. | 3 | $51 |
| Lifescan, Inc. | 2 | $49 |
| Cequr Corporation | 1 | $48 |
| Eisai Inc. | 2 | $41 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $36 |
| Companion Medical, Inc. | 2 | $31 |
| Senseonics, Incorporated | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,793 in reported general payments places this provider in the 75th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Other endocrinology, diabetes & metabolism in Branford
- Reza YavariBranford$9K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.